Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F14%3A43908711" target="_blank" >RIV/00216208:11120/14:43908711 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/S0140-6736(14)60803-5" target="_blank" >http://dx.doi.org/10.1016/S0140-6736(14)60803-5</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S0140-6736(14)60803-5" target="_blank" >10.1016/S0140-6736(14)60803-5</a>
Alternative languages
Result language
angličtina
Original language name
Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial
Original language description
Background: We assessed the efficacy, safety, and tolerability of ponesimod, an oral, selective, reversible modulator of sphingosine 1-phosphate receptor 1, in patients with moderate to severe chronic plaque psoriasis. Methods: Between Sept 22, 2010, andOct 24, 2012, patients with psoriasis area and severity index (PASI) scores higher than 10 were enrolled into this multicentre double-blind, phase 2 study. They received 20 mg or 40 mg ponesimod or placebo once daily for 16 weeks. Those with at least 50% reduction in PASI score at 16 weeks and who were receiving ponesimod were rerandomised to receive maintenance ponesimod therapy or placebo until week 28. The primary endpoint was reduction in PASI score from baseline of at least 75% (PASI75) at week 16. This study is registered with ClinicalTrials.gov, number NCT01208090. Findings: Of 326 patients initially randomised (20 mg ponesimod n=126, 40 mg ponesimod n=133, and placebo n=67) PASI75 was achieved at week 16 in 58 (46 0%), 64 (48 1
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FO - Dermatology and venereology
OECD FORD branch
—
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2014
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Lancet
ISSN
0140-6736
e-ISSN
—
Volume of the periodical
384
Issue of the periodical within the volume
9959
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
2036-2045
UT code for WoS article
000346353600025
EID of the result in the Scopus database
—